Tourmaline Bio Statistics
Total Valuation
Tourmaline Bio has a market cap or net worth of $570.80 million. The enterprise value is $332.48 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, before market open.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Tourmaline Bio has 25.69 million shares outstanding. The number of shares has increased by 53.98% in one year.
Current Share Class | 25.69M |
Shares Outstanding | 25.69M |
Shares Change (YoY) | +53.98% |
Shares Change (QoQ) | +0.25% |
Owned by Insiders (%) | 8.35% |
Owned by Institutions (%) | 63.39% |
Float | 13.93M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.97 |
P/TBV Ratio | 2.08 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | -20.70% |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.20M |
Employee Count | 74 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.15% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +58.15% |
50-Day Moving Average | 18.98 |
200-Day Moving Average | 18.61 |
Relative Strength Index (RSI) | 62.89 |
Average Volume (20 Days) | 211,141 |
Short Selling Information
The latest short interest is 2.63 million, so 10.24% of the outstanding shares have been sold short.
Short Interest | 2.63M |
Short Previous Month | 3.01M |
Short % of Shares Out | 10.24% |
Short % of Float | 18.89% |
Short Ratio (days to cover) | 13.99 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -102.45M |
Pretax Income | -35.69M |
Net Income | -88.47M |
EBITDA | -102.41M |
EBIT | -102.45M |
Earnings Per Share (EPS) | -$3.44 |
Full Income Statement Balance Sheet
The company has $249.31 million in cash and $196,000 in debt, giving a net cash position of $249.11 million or $9.70 per share.
Cash & Cash Equivalents | 249.31M |
Total Debt | 196,000 |
Net Cash | 249.11M |
Net Cash Per Share | $9.70 |
Equity (Book Value) | 279.86M |
Book Value Per Share | 10.90 |
Working Capital | n/a |
Full Balance Sheet Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Tourmaline Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -53.98% |
Shareholder Yield | -53.98% |
Earnings Yield | -15.21% |
FCF Yield | n/a |
Dividend Details Analyst Forecast
The average price target for Tourmaline Bio is $49.33, which is 122.01% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $49.33 |
Price Target Difference | 122.01% |
Analyst Consensus | Strong Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 0.48% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |